Introduction {#s1}
============

Human papillomavirus (HPV) infection can lead to a variety of human cancers,[@R1] including cervical cancer (CC), which is the fourth most common cause of cancer and a leading cause of mortality in women worldwide.[@R3] It has been estimated that approximately 989 000 Chinese women were diagnosed with CC and 305 000 died from it in 2015.[@R4] Despite improved multidisciplinary treatments, the prognosis of advanced CC is still poor, with a 5-year survival rate of approximately 15% for late-stage patients.[@R5]

CC screening as a secondary prevention is important in CC control. HPV DNA and liquid-based cytology have been widely used in CC screenings; however, there are limitations to both approaches.[@R6] Many studies have reported the use of new approaches, such as assessing E6/E7 mRNA and protein expression or p16^ink4a^ overexpression, in CC screening.[@R7] The identification and validation of new molecular biomarkers play an important role in CC prevention. Previous studies have identified recurrent genetic mutations in *PIK3CA*, *FBXW7*, *EP300*, *MAPK1*, *HLA*-B, *NFE2L2*, *TP53*, *ERBB2*, *ELF3* and *CBFB* in CC.[@R8] However, the patterns of cellular alterations and virus integrations in cervical lesions, especially in cervical intraepithelial neoplasia (CIN), are largely unknown.

Treatments for CC are mainly based on surgery and chemoradiotherapy. Recent advances in targeted therapies against specific somatic alterations have transformed the management of cancers in general.[@R9] The discovery of new therapeutic targets could improve the current strategies to combat CC, such as agents targeting the PI(3)K pathway.[@R10] Thus, it is necessary to evaluate genetic alterations in cancer and to subclassify cancers based on genetic alterations.

Here, we systematically analysed the genomic variation profiles of 102 tumour--normal pairs and 25 CIN specimens with matched germline DNA. Somatic mutations, copy number alterations (CNAs), genomic rearrangements and HPV integration events were identified and used to define the genomic landscape in CC and to find potential biomarkers for the screening and treatment of CC.

Methods {#s2}
=======

Samples {#s2a}
-------

This project and protocols were conducted according to the Declaration of Helsinki. Tumour tissues and matched adjacent normal tissues or peripheral blood were collected. Tissue cells of normal or CIN were collected from female patients attending a sexually transmitted disease clinic at Shanghai Skin Disease Hospital. Sample collection, HPV typing, liquid-based cytology and biopsy were performed under the guidelines or demands of the patients with appropriate informed consent.

Next-generation sequencing and data analysis {#s2b}
--------------------------------------------

Whole-genome sequencing (WGS) or whole-exome sequencing (WES), HPV probe-capture sequencing (HPCS) and transcriptome using RNAseq were performed as described in the online supplementary materials. Read alignment and processing were performed using the BWA,[@R11] Picard (<http://broadinstitute.github.io/picard/>) and GATK tools.[@R12] We detected somatic single nucleotide variants (SNVs), insertions and deletions (InDels), CNAs and structural variations (SVs) using MuTect,[@R13] Strelka,[@R14] Varscan2,[@R15] CLImAT[@R16] and Clipping REveals STructure (CREST).[@R17] MutSigCV and GISTIC V.2.0 were employed to analyse the genes significantly affected by mutations and CNAs.

Statistical analysis {#s2c}
--------------------

P values were calculated using Fisher's exact test, t-test, Mann-Whitney U test and Delong's test as indicated. Receiver operating characteristic (ROC) curves with the area under the curve (AUC) were performed to evaluate the specificity and sensitivity of HPV testing for detecting CC using pROC package.[@R18]

Data availability {#s2d}
-----------------

All the sequence data have been deposited in the database NCBI SRA: SRA315538 and the project number PRJNA305342.

See the online supplementary materials and methods for more detailed methods.

Results {#s3}
=======

Profiles of somatic mutations in CCs {#s3a}
------------------------------------

To explore the profiles of molecular variants in CC samples, we selected 102 paired samples, including tumours (95 HPV-positive cases and 7 HPV-negative cases) and matched-normal tissues (n=8) or peripheral blood (n=94) (see online [supplementary table S1](#SP1){ref-type="supplementary-material"}). We then performed WES analysis of 76 tumour-normal sample pairs using the Illumina HiSeq 2000 platform and the Ion Proton platform, WGS analysis of 27 tumour-normal samples using the HiSeq X-Ten platform and the complete genomics (CG) platform (one sample sequenced by WES and WGS), and transcriptome analysis of 6 tumour-normal samples (all six samples overlapped with WGS/WES) using the HiSeq 2000 platform (see online [supplementary figure S1](#SP2){ref-type="supplementary-material"} and [supplementary table S1](#SP1){ref-type="supplementary-material"}). The average depth of coverage was \~100× for WES data and \~30× (HiSeq X-Ten) or 100× (CG) for WGS (see online [supplementary table S2](#SP1){ref-type="supplementary-material"}), respectively.
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Using multiple tools, we identified 17 034 somatic mutations in the exons and splice regions, including 8479 missense, 3755 synonymous, 691 nonsense, 166 splice, 40 in-frame InDel, 112 frameshift, 11 initiation-site loss, 10 read-through and 3770 UTR mutations (see online [supplementary table S3](#SP1){ref-type="supplementary-material"}). There was an average of 167 exonic and splicing mutations (ranging from 2 to 1361) per sample, suggesting high heterogeneity in the CC samples. The mean and median exonic mutation rates were 3.53/Mb and 2.05/Mb, respectively ([figure 1A](#F1){ref-type="fig"}). These rates are in the same range as the rates observed in the majority of adult solid tumours.[@R19] In total, 91.9% (226/246) of the randomly selected somatic mutations were completely validated by mass spectrometry (MS) genotyping or Sanger sequencing (see online [supplementary table S3](#SP1){ref-type="supplementary-material"}).

![Genomic alteration profiles of cervical carcinomas. (A) Total mutational rates per Mb, including the non-silent and silent mutations in each sample. The HPV infection status, pathology type and International Federation of Gynecology and Obstetrics (FIGO) stage for all the cases are displayed below. (B) The alteration spectrum of the significantly mutated genes in 102 cervical cancers (CCs). The grey bar on the right indicates the q value calculated using MutsigCV. The frequency of non-silent mutations in each gene is shown on the left. (C) A summary of the significantly amplified or deleted genes in 102 CCs, with the frequency of each gene shown on the left.](jmedgenet-2018-105745f01){#F1}

Through mutation spectrum analysis, we observed a high C\>T transition rate and a high C\>G transversion rate in the CC samples, accounting for 55.0% and 18.9% of the total mutations, respectively (see online [supplementary figure S2A-S2B](#SP2){ref-type="supplementary-material"}). Context analysis revealed that Tp\*CpN\>(T/G) was the predominant mutation type, which is consistent with previous report.[@R8] (Tp\*CpW(W=A or T)\>(T/G)) mutations constituted 42.3% of all the mutations. It has been reported that the overexpression of the cytidine deaminases in the APOBEC family,[@R20] may cause this mutation signature. Indeed, transcriptomic analysis demonstrated that the APOBEC family member *APOBEC3H* was expressed at higher levels in CC samples than those in the adjacent normal tissues (p=0.02, online [supplementary table S4](#SP1){ref-type="supplementary-material"}), while other members of APOBEC family including *APOBEC3A*,*APOBEC3B*, *APOBEC3C*, *APOBEC3D*, *APOBEC3F*, *APOBEC3G* showed no significant dysregulation in the same samples (see online [supplementary table S4](#SP1){ref-type="supplementary-material"}, all p\>0.05). These data suggest that the mechanisms underlying the major APOBEC*3H*-characterised mutation types (Tp\*CpW \>(T/G)) play an important role in cervical carcinogenesis.

Driver mutations in CCs {#s3b}
-----------------------

To identify recurrently mutated genes, we analysed all somatic SNVs and InDels in 102 CC samples using MutsigCV.[@R19] Five genes showed a statistically significant level of recurrent mutations (with false-discovery rates (FDRs)\<0.1): *PIK3CA* (16.7%, 17/102), *FBXW7* (12.8%, 13/102), *MLL3* (7.8%, 8/102), *CASP8* (3.9%, 4/102) and *FADD* (3.9%, 4/102) ([figure 1B](#F1){ref-type="fig"} and online [supplementary table S5](#SP1){ref-type="supplementary-material"}). Although the results were not statistically significant, *FAT1* (8.8%, 9/102), *MLL2* (5.9%, 6/102) and *EP300* (5.9%, 6/102), which had high mutation rates and were enriched in truncation mutations (see online [supplementary table S6](#SP1){ref-type="supplementary-material"}), were predicted to have roles in CC. Mutations in these genes were validated by MS genotyping or Sanger sequencing (see online [supplementary table S3](#SP1){ref-type="supplementary-material"}). Recurrent mutations in *PIK3CA*, *FBXW7* and *EP300*, which have been previously reported in CC,[@R8] were also identified in our cohort. The majority of *PIK3CA* mutations clustered in the helical domain (73.7%, including four E542K, one E545G and nine E545K) but not in the kinase domain (15.8%, 3/19). Moreover, several hotspot mutations were identified in *FBXW7* (three R465C, two R465H, five R505G and one R505L), and nonsense mutations were frequently observed in *EP300* (50%, 3/6; online [supplementary table S3](#SP1){ref-type="supplementary-material"}). We found recurrent mutations in *CASP8*, *FADD*, *MLL2*, *MLL3* and *FAT1*, which are, to our knowledge, reported here for the first time in CC ([figure 1B](#F1){ref-type="fig"}; online [supplementary table S5-S6](#SP1){ref-type="supplementary-material"}). Mutations in these genes were more frequent than those previously reported in the COSMIC database (see online [supplementary table S6](#SP1){ref-type="supplementary-material"}).

In our cohort, *CASP8* and *FADD* each harboured four mutations, most of which were inactivating mutations (75%, 6/8; [figure 1B](#F1){ref-type="fig"} and online [supplementary table S6](#SP1){ref-type="supplementary-material"}). Interestingly, although the results were not statistically significant (p=0.15), *FADD* mutations were found only in cases without *CASP8* mutations ([figure 1B](#F1){ref-type="fig"}). CASP8 is normally recruited to death receptors by binding to the apoptotic adaptor FADD, which subsequently initiates caspase-mediated apoptosis. Loss of function of these two genes may promote carcinogenesis by inducing resistance to cell death.

The *MLL2* and *MLL3* genes, which each encodes a histone 3-lysine 4 methyltransferase, contained truncation mutations in 85.7% (6/7) and 77.8% (7/9) of the samples, respectively ([figure 1B](#F1){ref-type="fig"} and online [supplementary table S6](#SP1){ref-type="supplementary-material"}). Both genes are frequently mutated in various tumours, including bladder cancer[@R23] and breast cancer.[@R24] The enrichment in loss-of-function mutations in these genes suggested that the *MLL2* and *MLL3* genes play roles in tumour suppression in multiple cancer types, including CC.

Another frequently mutated gene was *FAT1*, which was mutated in 8.8% (9/102) of tumours ([figure 1B](#F1){ref-type="fig"} and online [supplementary table S6](#SP1){ref-type="supplementary-material"}). Reportedly, recurrent somatic mutations in *FAT1* lead to aberrant Wnt activation in multiple human cancers.[@R25] Mutations in related family members, such as *FAT2*, *FAT3* and *FAT4*, were also found in our cohort (see online [supplementary table S3](#SP1){ref-type="supplementary-material"}). *FAT2* gene-silencing by small interfering RNAs promoted the growth of CC cells, suggesting that *FAT2* may be a new tumour-suppressor gene in CC (see online [supplementary figure S2C](#SP2){ref-type="supplementary-material"}).

Somatic CNAs and structure variations in CCs {#s3c}
--------------------------------------------

In this study, we first compared differences in CNAs between WGS at a low depth and WES in eight samples. The results showed a high correlation across platforms (average correlation coefficient=0.93, 0.87--0.97; online [supplementary figure S3A](#SP2){ref-type="supplementary-material"}), suggesting that the WES data were also suitable for CNA analysis.

We performed CNA analysis on the WES or WGS data from 102 sample pairs, using a modified CLImAT algorithm.[@R16] The results revealed that 17.6% (18/102) of the samples presented polyploid genome features (the average ploidy was \>3.5), of these, 52.2% (14.8%--76.5%) of the chromosomal regions contained CNAs (online [supplementary figures S3B-S3C](#SP2){ref-type="supplementary-material"}); 82.4% (84/102) of the samples presented diploid genome features, and of these, 23.8% (0.0%--59.7%) of the chromosomal regions contained CNAs. This value was significantly lower than the proportion observed in the polyploidy group (p\<0.05, Fisher's exact test; online [supplementary figure S3B](#SP2){ref-type="supplementary-material"}).

Among the 84 diploid samples, genome-wide segmented copy number analysis showed that many chromosome arms had undergone large-scale gains or losses in copy number, with frequent gains observed on chromosomes 1q, 3q, 5p, 8q, 9q and 20q and frequent losses observed on chromosomes 3p, 4p, 4q, 6q, 8p, 11p, 11q, 17p, 18q and 19p (see online [supplementary table S7](#SP1){ref-type="supplementary-material"}). The overall CNA pattern was broadly consistent with the results of other published studies of CC.[@R8]

We identified 23 focal events using the GISTIC2.0 algorithm,[@R28] including 10 amplification peaks and 13 deletion peaks that involved 2541 genes (see online [supplementary figure S3D and table S8](#SP1 SP2){ref-type="supplementary-material"}). These genes included well-known oncogenes and tumour-suppressor genes, such as *BIRC3* (11q22.1), *PIK3CA*/*SOX2* (3q29), *EGFR* (7P11.2), *CCND1* (11q13.3), *BAP1* (3P11.2) and *ATM* (11q23.3) ([figures 1C and 2A](#F1 F2){ref-type="fig"}).

![Structural alterations in cervical carcinomas. (A) A genome-wide view of copy number alterations (CNAs). The upper regions represent amplification (red), the lower regions represent deletion (blue) and the peak regions represent the potential driver genes. The three inserts show the common CNA regions (regions between two vertical lines) of the three potential drivers, including *TERT, BIRC2/BIRC3* and *E2F1*. (B and C) Chromothripsis in two samples: CC-X009 (B) and CC-X019 (C). The upper image shows the SVs that are coloured red (insertion), blue (deletion), orange (inversion), green (intrachromosome translocation) and grey (interchromosome translocation). The lower images show the copy number (CN), logR ratio and B allele frequency (BAF).](jmedgenet-2018-105745f02){#F2}

Considering the limitations of the GISTIC tool, we used an in-house-designed algorithm to identify more potential CNA peaks. We identified seven peaks with a high ratio that involved 1461 genes (see online [supplementary table S8](#SP1){ref-type="supplementary-material"}). For example, *MCL1*, which is one of the most frequently amplified genes in human cancer,[@R29] was amplified in 39.3% of the CC samples. Another frequently amplified gene, *E2F1* (20q11.21), is a key transcription factor controlling the cell cycle and was amplified in 25.0% of the CC samples.

CREST software[@R17] was used to identify SVs in CCs. A total of 770 SVs were identified, including 109 interchromosomal translocations, 161 intrachromosomal translocations, 115 insertions and 385 deletions (see online [supplementary figure S3E and table S9](#SP1 SP2){ref-type="supplementary-material"}). Chromothripsis occurred in two samples: CC-X009 and CC-X019 ([figure 2B,C](#F2){ref-type="fig"}). We therefore deemed it useful to further examine the relationship between SVs and cervical carcinogenesis.

Driver pathway analysis in CCs {#s3d}
------------------------------

Using the list of driver genes that we found to be altered by mutations or copy number changes, we searched for over-represented pathways with known roles.[@R30]

The results showed that well-defined cancer-related pathways, including the RTK/RAS/PI(3)K, cell cycle and apoptosis pathways, were altered in 88%, 74% and 73% of cases, respectively ([figure 3A](#F3){ref-type="fig"}). The activation of *EGFR*, *ERBB2*, *ERBB3*, *ERBB4* (mutations and amplifications) and *NRAS* (amplification) affected the RTK/RAS pathway, and the activation of *PIK3CA* (mutations and amplifications) predominately resulted in the dysregulation of the PI(3)K/AKT/mTOR pathway. Altered genes in the cell-cycle pathway were mainly related to the G1/S transition, including activated *CCND1*, *CDK4*, *E2F1* and *E2F3* (amplifications) and inactivated *CDKN1C*, *CDKN2D* and *RB1* (deletions). We also identified mutations that frequently affect the apoptosis pathway, including deletions and mutations of *FAS*, *TNF*, *FADD* and caspases 3, 6, 7, 8, 9 and 10. In addition, the amplification of the *BIRC2*/*3* genes on 11q22 played a role in the deregulation of the cancer cell-death pathway.

![Frequently altered pathways and potential therapeutic targets and drugs in cervical carcinomas. Somatic mutations and copy number alterations (CNAs) in components of the RTK/RAS/PI(3)K, apoptosis, chromatin remodelling, cell cycle, oxidative stress response and squamous differentiation pathways. Red, activating genetic alterations; blue, inactivating genetic alterations. The percentages shown indicate the activation or inactivation of at least one allele. (B) The left panel represents the alteration frequency for each potential drug-targeted gene in the different pathways. The middle panel represents the recurrent somatic mutations (which reoccurred in this cohort or were previously reported in the COSMIC database) and CNAs (≥5 copies). The right panel represents the potential drugs that can be used against the alterations shown in the middle panel.](jmedgenet-2018-105745f03){#F3}

Genes involved in the chromatin remodelling pathway were recurrently altered by mutations or CNAs. Potential driver gene analysis identified several histone modifiers (*MLL2*, *MLL3* and *EP300*), and many other genes in this pathway were also mutated or deleted. In addition, 87% of cases had mutations or deletions in components of the SWI/SNF nucleosome remodelling complex, including *ARID1A*, *ARID1B*, *SMARCAD1*, *SMARCA4* and *PBRM1*. We also found alterations in genes involved in oxidative stress response in 59% of cases, including mutations and deletions in *CUL3* and *KEAP1*, as well as amplifications and mutations in *NFE2L2*. Specifically, genes with known roles in squamous cell differentiation were also frequently altered. Amplifications in *SOX2* and *TP63* were widely identified in CC samples as were mutations and deletions in NOTCH family members (*NOTCH1/2/3*).

To identify genes that could potentially be targeted by drugs in the treatment of CC, we used the TARGET (tumour alterations relevant for genomics-driven therapy) database[@R31] for the integrated analysis of mutations and CNAs. The results showed that 34 genes with targetable oncogenic mutations were revealed in 55.9% (57/102) of the samples. Of these 57 samples, each contained at least one mutation or one CNA (≥five copies) in a gene that predicts sensitivity or resistance to anticancer agents (ranging from one to five) ([figure 3B](#F3){ref-type="fig"}). These results suggested that patients with CC may potentially benefit from next-generation sequencing (NGS)-based molecular genotyping and that newly identified genetic alterations may serve as potential candidate drug targets for CC.

Somatic mutations in both CINs and CCs {#s3e}
--------------------------------------

To study the relationship between somatic mutations and the initiation and progression of CC, we performed WES in 35 additional sample pairs, including 10 CIN1, 9 CIN2, 6 CIN3 and paired blood cell DNA, as well as 10 CC tumour-normal specimens. The average depth of coverage was 95×, and the average percentage of region covered at least 1× was 99.42% (see online [supplementary table S2](#SP1){ref-type="supplementary-material"}). We found 1747 SNVs and 27 InDels in all 35 samples, 1743 of which occurred in CCs and involved 1552 genes (see online [supplementary table S10](#SP1){ref-type="supplementary-material"}). Interestingly, 31 gene mutations were detected in 52% (13/25) of the CIN specimens, and 54.8% (17/31) of these mutations (in 32% (8/25) of the CIN specimens) occurred in genes that also mutated in CCs ([figure 4](#F4){ref-type="fig"}). All mutations observed in CINs were validated manually by IGV or by Sanger sequencing (see online [supplementary figure S4](#SP2){ref-type="supplementary-material"}). Our current findings suggested that mutations could be detected in CIN samples. These results provide a solid foundation for further study of the CC pathogenesis and provide new molecular biomarkers for the early warning and screening of CC.

![Somatic mutations in cervical intraepithelial neoplasia (CINs) and cervical carcinomas. All somatic mutations that occurred in the 25 CINs and 112 cervical cancers (CCs) are shown in the left panel, with each row indicating a gene and each column representing a sample. Genes mutated in the CIN specimens are zoomed in and shown in the right panel.](jmedgenet-2018-105745f04){#F4}

HPV DNA integrations in both CINs and CCs {#s3f}
-----------------------------------------

To study the relationship between HPV integration in the human genome and the occurrence and development of CC, we performed an HPCS technology. We analysed HPV integration breakpoints in 25 normal cervical samples (including 18 HPV-negative and 7 HPV-positive samples), 44 CIN samples (including 24 CIN1 and 20 CIN2-3 samples) and 45 CC samples (see online [supplementary table S1](#SP1){ref-type="supplementary-material"}).

A total of 2466 HPV integration breakpoints were identified in 84.3% (75/89) of the abnormal samples, including 97.8% (44/45) of the CC samples and 70.5% (31/44) of the CIN samples ([figure 5A](#F5){ref-type="fig"}, online [supplementary table S2 and S11](#SP1){ref-type="supplementary-material"}). To confirm the HPV integration events, we randomly chose 29 integration junctions for validation using Sanger sequencing. The results showed that 82.8% (24/29) of the integration junctions were validated (see online [supplementary table S11](#SP1){ref-type="supplementary-material"}), indicating that the results were reliable for further analysis.

![Human papillomavirus (HPV) integration events in the normal cervical samples, cervical intraepithelial neoplasia (CIN) samples and cervical carcinomas. (A) The relative number of HPV integration events in the normal cervix samples that were HPV positive or HPV negative and in the CIN1, CIN2-3 and cervical cancer (CC) samples. All panels are aligned with the vertical tracks representing 114 individuals. (B) The relative number of the supported reads from the normal cervix, CIN1, CIN2-3 and CC samples that were integration-positive. The X-axis represents 78 individuals, the Y-axis represents the relative number of supported reads with integrations and the Z-axis represents the top 10 integration events in each sample. (C) HPV types that were integrated into different samples are shown. The right panel indicates the HPV types (high-risk strains in the upper panel and low-risk strains in the lower panel); the upper panel indicates the clinical stage, including the normal cervical samples that were HPV negative (light blue) and HPV positive (blue) as well as the CIN1 (dark blue), CIN2-3 (orange) and cervical carcinoma (red) samples.](jmedgenet-2018-105745f05){#F5}

As expected, no HPV integration breakpoint was detected in the normal samples with HPV negative. HPV integration events were found in 42.8% (3/7) of the HPV-positive normal cervical samples ([figure 5A](#F5){ref-type="fig"}). Moreover, we found that HPV integration breakpoints had more supported reads in CC samples than those in the normal samples (p=2.88E-05, Mann-Whitney U test), CIN1 samples (p\<2.2E-16, Mann-Whitney U test) and CIN2-3 samples (p=3.79E-09, Mann-Whitney U test), whereas the HPV integration breakpoints had more supported reads in the CIN samples than those in the normal samples (p=8.78E-05 for CIN2-3 vs normal and p=1.94E-02 for CIN1 vs normal, Mann-Whitney U test; [figure 5B](#F5){ref-type="fig"}). Interestingly, we found that the integrations of certain HPV strains in the CCs, including HPV16, 18, 33 and 58, had also occurred in the CIN1 and CIN2-3 samples ([figure 5C](#F5){ref-type="fig"}). The integration occurrence of high-risk HPV was higher than that of low-risk HPV in CINs and CC as compared with normal tissues with HPV positive (p=0.004 for CIN1, p=0.0015 for CIN2-3 and p=1.34e-06 for CC, respectively; Fisher's exact test; online [supplementary figure 5B](#SP2){ref-type="supplementary-material"}). These data suggest that oncogenic HPV integration events may occur early in preneoplastic lesions.

To validate the diagnostic performance using HPV integration, ROC curve analysis was conducted in CC and CIN compared with normal individuals (see online [supplementary table S12 and figure S5](#SP1 SP2){ref-type="supplementary-material"}). We found that HPV integration alone or combined with HPV DNA testing could distinguish CC and normal. We used multiple HPV integration as biomarkers to estimate its diagnostic value, the AUC values were 76.5% (95% CI 64.17% to 88.83%), 81.2% (95% CI 69% to 93.4%) and 95.5% (95% CI 88.93% to 100%) for CIN1, CIN2-3 and CC, respectively. Specifically, HPV16/18 integration exclusively showed an AUC value of 96.7% (95% CI 92.98% to 100%; DeLong's test) for CC versus normal, suggesting an ideal biomarker for detecting CC. The combination of HPV integration and DNA testing had a trend towards higher AUC value than HPV DNA testing (DeLong's test; online [supplementary table S12](#SP1){ref-type="supplementary-material"}) in CIN and CC, suggesting a better biomarker for cervical cancer screening.

Our results showed that HPV integration breakpoints are distributed over the whole HPV genome (see online [supplementary figure S6A](#SP2){ref-type="supplementary-material"}). Statistical analyses indicated that integration junctions were more likely to be located in the E1 (p=7.2E-4) and E2 genes (p=4.5E-4), whereas integration junctions were less likely to be located in the E6 gene (p=4.7E-2), the long control region (LCR, p=2.8E-3), the L1 gene (p=2.8E-2) or the L2 gene (p=1.2E-3; online [supplementary figure S6B](#SP2){ref-type="supplementary-material"}). Our data suggested that intact forms of the E6 gene and the LCR were more likely to be observed in the human genome.

Local algorithms predicted that the integrated HPV fragment sizes ranged from 43 to 7885 bp (see online [supplementary figure S6C](#SP2){ref-type="supplementary-material"}). To validate the HPV fragment sizes predicted by NGS, we randomly selected 20 HPV integration events and performed long PCR to amplify the full-length fragments. Junctions residing on both sides of the six successful amplicons were validated by Sanger sequencing (see online [supplementary figure S6D](#SP2){ref-type="supplementary-material"}). The results revealed a 6649 bp HPV integrant in the CC-H011 genome (see online [supplementary figure S7A](#SP2){ref-type="supplementary-material"}), and the other five HPV fragments, ranging from 1897 to 4648 bp, were inserted into the human genome of CC samples (see online [supplementary figures S7B-7F](#SP2){ref-type="supplementary-material"}). These results indicated that HPV fragments of varied fragment sizes randomly insert into the human genome. Transcriptomic data showed that integration of the E4, E5, E6 and E7 genes led to the expression of full length of viral genes (see online [supplementary figure S7G](#SP2){ref-type="supplementary-material"}), whereas integration of the E1, E2, L1 and L2 genes resulted in only partial transcription or no transcription (see online [supplementary figure S7G](#SP2){ref-type="supplementary-material"}). These data indicate that although all HPV genes can be integrated into the host genome, only the oncogenes are completely expressed.

Furthermore, HPV integration sites were found within the exons or introns of 886 human genes, including *MYC*, *RAD51B*, *FHIT*, *KIF1B*, *ALK* and *PDE4D* (see online [supplementary figure S8A and table S11](#SP1 SP2){ref-type="supplementary-material"}). We identified 53 integration breakpoints in the *MYC* gene and its flanking regions (the upstream or downstream 500K) in 24.4% (11/45) of the samples (see online [supplementary table S11](#SP1){ref-type="supplementary-material"}). Reportedly, integration breakpoints are closely associated with genomic instability.[@R32] Indeed, we found (1) focal amplification of the *MYC* gene in CC-H011 and CC-H012, in which the HPV integration breakpoints were located in regions both upstream and downstream of the *MYC* gene; (2) a 17 Mb gain in 8q that included integration into *MYC* in CC-H024, in which the HPV integration breakpoints were located \~240 kb upstream of *MYC* and (3) focal amplification of *POU5F1B* (317 kb upstream of *MYC*) in CC-H044, in which HPV integration breakpoints were located both upstream and downstream of *POU5F1B* (see online [supplementary figure S8B](#SP2){ref-type="supplementary-material"}). Focal amplification may be identified using a 'looping' model, as previously reported.[@R32] Gene mutations were also enriched in the host cell genome regions adjacent to the integration breakpoints (p=9.05E-9) in addition to the CNAs and SVs (p\<2.2E-16 and p=2.17E-7, respectively; online [supplementary figure S8C](#SP2){ref-type="supplementary-material"}). Therefore, the host genome instability caused by HPV integration may drive cervical carcinogenesis.

Discussion {#s4}
==========

Here, we report a comprehensive analysis of genomic alterations and HPV integrations in normal cervical samples, CINs and CCs. To our knowledge, this study is the first to combine cellular genomic alterations and virus integration profiles in both CCs and CIN, to document the mechanisms that underline cervical carcinogenesis and provide potential biomarkers for the screening and therapy.

We report comprehensive mutation profile of CINs and CC samples and a comparison analysis of mutation profiling was conducted. It is worth noting that frequently mutant genes, such as *PIK3CA* in CC, were not identified in CINs. Moreover, *TP53* mutation, a highly prevalent event in various cancers, was rarely identified in both CC and CINs. These observations were consistent with previous study that low mutation frequency of the *TP53* and *PIK3CA* genes were found in CIN3 samples.[@R33] Interestingly, certain other genes that were mutated in CCs were also mutated in CINs, some of which were reported to be related with cancer development, including *PTBP3*,[@R34] *ESX1*,[@R35] *PER3* [@R36] and *CIP2A*.[@R38]

Consistent with previous reports,[@R39] we identified HPV integration in CIN samples and normal cervical samples with HPV infection. However, Liu *et al* did not find HPV integration in CIN1 using HIVID.[@R40] Particularly, HPV integrations were identified especially in CIN1 in this study and the study by Hu *et al*.[@R39] The reason might be ascribed to the discrepancies in sample size and sequencing depth (\~10× for samples by Liu *et al*,[@R41] \~6427× for specimens by Hu *et al* and \~61 217× in our cohort, respectively). And the integration events were validated by Sanger with a ratio of 82.8%, indicating that high-depth HIVID could be a sensitive method to detect integrated HPV. The different types of virus integration spectra were observed in different stages of cervical samples. HPV16 and HPV18 are the dominant HPV types integrated into CC samples. Integration of multiple HPV types, including HPV16, HPV18, HPV33 and HPV58, has been identified in CIN samples. Big data of CC screening showed that HPV 16, 33 and 58 were the most common HPV types in high-grade squamous intraepithelial lesions in Chinese women.[@R42] It is possible that different integrated HPV types indicate different outcomes of CIN samples, which may require further follow-up and validation for these patients. Novel disease-specific biomarkers, such as gene mutations and HPV integrations, may serve as secondary markers after positive HPV DNA tests to identify women with prevalent precancers who require immediate colposcopy or treatment.

In clinical practice, advanced patients with CC often choose platinum-containing chemotherapies, but their prognosis remains poor. Therefore, it is necessary to search for new therapeutic drugs, especially targeted drugs, via NGS-based molecular genotyping. Our results showed that 55.9% of the CC samples harboured at least one actionable alteration. PI(3)K/AKT/mTOR inhibitors,[@R43] tyrosine-kinase inhibitors,[@R44] receptor tyrosine kinase antibodies[@R45] and cyclin-dependent kinase inhibitors[@R46] have been approved by the Food and Drug Administration or are in clinical trials for several cancers but not for CCs. Patients with alterations in the targets of these drugs might benefit from targeted therapies. In addition, 50.9% (29/57) of these patients harboured more than one actionable alteration, indicating that combinational therapies may allow patients with CC to receive greater treatment benefits.

In summary, we systematically analysed the genomic variations and HPV integration profiles of CIN and CC, our findings provide the foundation for detecting precancerous lesions early and developing new biotechnology for the screening and therapy of CC.
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